AngioDynamics, Inc.（ANGO）股票分析ANGOAngioDynamics, Inc.

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AngioDynamics is not a good buy right now due to its significant recent losses and negative market sentiment. The current price is $11.52, with a 5-day change of -23.76%, indicating a sharp decline. Additionally, the RSI is at 14.695, suggesting the stock is oversold but may not recover soon. The company reported a loss of $0.04 per share, which was better than expected, but the actual loss under GAAP was $0.17 per share, highlighting ongoing financial difficulties. The main risk is the forecasted loss of $0.24 to $0.29 per share for fiscal 2027, indicating potential for further declines in stock value.

5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.